Literature DB >> 12117599

Activation of mGlu1 but not mGlu5 metabotropic glutamate receptors contributes to postischemic neuronal injury in vitro and in vivo.

Elena Meli1, Roberta Picca, Sabina Attucci, Andrea Cozzi, Fiamma Peruginelli, Flavio Moroni, Domenico E Pellegrini-Giampietro.   

Abstract

In order to investigate the involvement of mGlu1 and mGlu5 metabotropic glutamate receptors in the development of postischemic neuronal death, we examined the effects of selective agonists and antagonists in models of cerebral ischemia in vitro and in vivo. In murine cortical cell cultures and rat organotypic hippocampal slices exposed to oxygen and glucose deprivation (OGD), the mGlu1 antagonists 1-aminoindan-1,5-dicarboxylic acid (AIDA; 300 microM), (S)-(+)-2-(3'-carboxybicyclo[1.1.1]pentyl)-glycine (CBPG; 300 microM), 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester (CPCCOEt; 10-30 microM) and (+)-2-methyl-4-carboxyphenylglycine (LY367385; 30-100 microM) reduced neuronal loss when added to the medium during OGD and the subsequent 24-h recovery period. On the contrary, the potent and selective mGlu5 antagonist methyl-6-(phenylethynyl)-pyridine (MPEP; 0.1-1 microM) did not exhibit neuroprotection in any of these in vitro models. Incubation with the nonselective mGlu1 and mGlu5 agonist 3,5-dihydroxyphenylglycine (3,5-DHPG; 300 microM) but not with the mGlu5 agonist (RS)-2-chloro-5-hydroxyphenylglycine (CHPG; 1 mM) enhanced the severity of OGD-induced neuronal damage. In gerbils subjected to global ischemia, intracerebroventricular administration of AIDA (100 nmol two times) or CBPG (300 nmol, two times) afforded consistent protection against CA1 pyramidal cell death, whereas MPEP (10 pmol i.c.v two times and 10 mg/kg i.p two times) failed to reduce postischemic hippocampal damage. Our results suggest that activation of mGlu1 but not mGlu5 receptor contributes to postischemic neuronal injury.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12117599     DOI: 10.1016/s0091-3057(02)00834-1

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  6 in total

1.  Treadmill pre-training suppresses the release of glutamate resulting from cerebral ischemia in rats.

Authors:  Jie Jia; Yong-Shan Hu; Yi Wu; Hui-Xian Yu; Gang Liu; Da-Nian Zhu; Chun-Mei Xia; Zhi-Juan Cao; Xi Zhang; Qing-Chuan Guo
Journal:  Exp Brain Res       Date:  2010-06-10       Impact factor: 1.972

2.  Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors.

Authors:  Paul M Lea; Vilen A Movsesyan; Alan I Faden
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

Review 3.  Huntington's disease and Group I metabotropic glutamate receptors.

Authors:  Fabiola M Ribeiro; Rita G W Pires; Stephen S G Ferguson
Journal:  Mol Neurobiol       Date:  2010-12-09       Impact factor: 5.590

4.  Glutamate regulates the frequency of spontaneous synchronized Ca2+ spikes through group II metabotropic glutamate receptor in cultured mouse cortical networks.

Authors:  Fumie Yasumoto; Takayuki Negishi; Yoshiyuki Ishii; Shigeru Kyuwa; Yoichiro Kuroda; Yasuhiro Yoshikawa
Journal:  Cell Mol Neurobiol       Date:  2004-12       Impact factor: 5.046

5.  Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post-ischaemic brain damage.

Authors:  F Moroni; L Formentini; E Gerace; E Camaioni; D E Pellegrini-Giampietro; A Chiarugi; R Pellicciari
Journal:  Br J Pharmacol       Date:  2009-05-05       Impact factor: 8.739

6.  Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage.

Authors:  Marta Motolese; Federica Mastroiacovo; Milena Cannella; Domenico Bucci; Anderson Gaglione; Barbara Riozzi; Robert Lütjens; Sonia M Poli; Sylvain Celanire; Valeria Bruno; Giuseppe Battaglia; Ferdinando Nicoletti
Journal:  Mol Brain       Date:  2015-10-24       Impact factor: 4.041

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.